LEXICON PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $49.8M | $31.1M | $1.2M | $139,000 | $298,000 |
| Cost of revenue | $274,000 | $616,000 | $85,000 | $0 | $0 |
| Selling, general & administrative | $37.3M | $143.1M | $114.0M | $48.1M | $32.3M |
| Research and development | $61.1M | $84.5M | $58.9M | $52.8M | $55.0M |
| Operating expenses | — | — | — | $100.9M | $87.4M |
| Operating income | -$48.9M | -$197.1M | -$171.8M | -$100.8M | -$87.1M |
| Interest expense | — | — | — | $2.8M | $802,000 |
| Pretax income | — | — | — | — | -$87.8M |
| Income tax expense | — | $0 | $0 | $0 | $0 |
| Net income | -$50.3M | -$200.4M | -$177.1M | -$101.9M | -$87.8M |
| Balance Sheet | |||||
| Cash and equivalents | $34.3M | $66.7M | $22.5M | $46.3M | $64.1M |
| Current assets | $101.9M | $246.2M | $176.5M | $140.9M | $88.9M |
| Total assets | $185.0M | $298.4M | $229.4M | $194.3M | $136.9M |
| Current liabilities | $20.9M | $45.2M | $31.5M | $23.2M | $22.1M |
| Total liabilities | $77.4M | $152.5M | $136.3M | $77.2M | $23.3M |
| Total debt | — | — | — | $48.6M | — |
| Stockholders' equity | $107.5M | $145.9M | $93.1M | $117.1M | $113.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$67.9M | -$178.8M | -$161.9M | -$88.9M | -$87.0M |
| Depreciation and amortization | $621,000 | $534,000 | $554,000 | $427,000 | $292,000 |
| Stock-based compensation | $12.5M | $13.5M | $14.3M | $11.5M | $10.6M |
| Capital expenditure | $0 | $1.0M | $470,000 | $1.3M | $1.2M |
| Free cash flow | -$67.9M | -$179.8M | -$162.4M | -$90.2M | -$88.2M |
| Share repurchases | — | $1.7M | $824,000 | $864,000 | $2.7M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 444.2M · Free float 46.2%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.